Alterations of fibrin network structure mediated by dermatan sulfate
- PMID: 22987196
- DOI: 10.1007/s11239-012-0804-9
Alterations of fibrin network structure mediated by dermatan sulfate
Abstract
Dermatan sulfate (DS) is well-known for its anticoagulant activity through binding to heparin cofactor II (HCII) to enhance thrombin inhibition. It has also been reported that DS has a profibrinolytic effect. We have evaluated the effects of DS solutions (4-20 μg/mL) on the formation (by kinetic studies), structure (by electron microscopy and compaction assays) and lysis (with urokinase-type plasminogen activator) of plasma fibrin networks. The results showed that DS significantly prolonged the lag phase and decreased the fibrin formation rate and the optical density of the final networks versus control, in a concentration dependent way. DS-associated networks presented a minor network percentage compared with control, composed of lower number of fibers per field, which resulted significantly thinner and longer. Moreover, DS rendered gels more sensible to rupture by centrifugal force and more susceptible to lysis. When fibrin formation kinetic assays were performed with purified fibrinogen instead of plasma, in the absence of HCII, the optical density of final DS-associated networks was statistically lower than control. Therefore, a direct effect of DS on the thickness of fibers was observed. Since in all in vitro assays low DS concentrations were used, it could be postulated that the fibrin features described above are plausible to be found in in vivo thrombi and therefore, DS would contribute to the formation of less thrombogenic clots.
Similar articles
-
Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators.Thromb Res. 2007;120(5):745-52. doi: 10.1016/j.thromres.2006.12.014. Epub 2007 Jan 31. Thromb Res. 2007. PMID: 17270255
-
Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates.Arterioscler Thromb. 1993 Aug;13(8):1213-7. doi: 10.1161/01.atv.13.8.1213. Arterioscler Thromb. 1993. PMID: 8343496
-
Lytic and mechanical stability of clots composed of fibrin and blood vessel wall components.J Thromb Haemost. 2013 Mar;11(3):529-38. doi: 10.1111/jth.12112. J Thromb Haemost. 2013. PMID: 23279194 Free PMC article.
-
Dermatan sulphate as an antithrombotic drug.Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):303-7. doi: 10.1159/000073586. Pathophysiol Haemost Thromb. 2002. PMID: 13679662 Review.
-
Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate.Curr Pharm Des. 2004;10(9):939-49. doi: 10.2174/1381612043452794. Curr Pharm Des. 2004. PMID: 15078125 Review.
Cited by
-
Fibrin Formation, Structure and Properties.Subcell Biochem. 2017;82:405-456. doi: 10.1007/978-3-319-49674-0_13. Subcell Biochem. 2017. PMID: 28101869 Free PMC article. Review.
-
Fibrin mechanical properties and their structural origins.Matrix Biol. 2017 Jul;60-61:110-123. doi: 10.1016/j.matbio.2016.08.003. Epub 2016 Aug 20. Matrix Biol. 2017. PMID: 27553509 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical